$6.60
6.54% yesterday
Nasdaq, Nov 25, 09:48 pm CET
ISIN
US50015M1099
Symbol
KOD
Sector
Industry

Kodiak Sciences, Inc. Stock price

$6.43
+2.69 71.93% 1M
+3.36 109.45% 6M
+3.39 111.51% YTD
+3.89 153.15% 1Y
-93.45 93.56% 3Y
-19.96 75.63% 5Y
-3.73 36.71% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.24 3.88%
ISIN
US50015M1099
Symbol
KOD
Sector
Industry

Key metrics

Market capitalization $338.37m
Enterprise Value $313.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.83
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-204.04m
Free Cash Flow (TTM) Free Cash Flow $-147.25m
Cash position $197.86m
EPS (TTM) EPS $-3.65
P/E forward negative
Short interest 4.01%
Show more

Is Kodiak Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Kodiak Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Kodiak Sciences, Inc. forecast:

1x Buy
13%
4x Hold
50%
3x Sell
38%

Analyst Opinions

8 Analysts have issued a Kodiak Sciences, Inc. forecast:

Buy
13%
Hold
50%
Sell
38%

Financial data from Kodiak Sciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 27 27
18% 18%
-
-27 -27
18% 18%
-
- Selling and Administrative Expenses 9.72 9.72
64% 64%
-
- Research and Development Expense 141 141
35% 35%
-
-177 -177
33% 33%
-
- Depreciation and Amortization 27 27
18% 18%
-
EBIT (Operating Income) EBIT -204 -204
29% 29%
-
Net Profit -192 -192
29% 29%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kodiak Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kodiak Sciences, Inc. Stock News

Neutral
PRNewsWire
12 days ago
PALO ALTO, Calif. , Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024.
Neutral
PRNewsWire
15 days ago
PALO ALTO, Calif. , Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences.
Neutral
PRNewsWire
about one month ago
PALO ALTO, Calif. , Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois.
More Kodiak Sciences, Inc. News

Company Profile

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Head office United States
CEO Victor Perlroth
Employees 111
Founded 2009
Website www.kodiak.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today